Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer.
direct-acting antiviral
hepatic resection
hepatitis C virus
hepatocellular carcinoma
propensity score matching
radiofrequency ablation
recurrence
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
04 May 2022
04 May 2022
Historique:
received:
19
04
2022
revised:
29
04
2022
accepted:
29
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
15
5
2022
Statut:
epublish
Résumé
It remains unclear whether hepatocellular carcinoma (HCC) recurrence in hepatitis C virus (HCV)-infected patients can be suppressed by the elimination of the virus using direct-acting antivirals (DAAs) after radical HCC treatment. We evaluated the sustained inhibitory effect of DAAs on HCC recurrence after curative treatment. This multicenter retrospective study included 190 HCV-positive patients after radical treatment for early-stage HCC. Patients were classified into the DAA treatment group (n = 70) and the non-DAA treatment group (n = 120) after HCC treatment. After propensity score matching (PSM), 112 patients were assessed for first and second recurrences using the Kaplan-Meier method and analyzed using a log-rank test. The first recurrence rates at 1 and 3 years were 3.6% and 42.1% in the DAA treatment group and 21.7% and 61.9% in the non-DAA treatment group, respectively (
Identifiants
pubmed: 35565424
pii: cancers14092295
doi: 10.3390/cancers14092295
pmc: PMC9103530
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Hepatol. 2016 Oct;65(4):734-740
pubmed: 27288051
Liver Cancer. 2019 Mar;8(2):121-129
pubmed: 31019902
Hepatology. 2018 Aug;68(2):449-461
pubmed: 29476694
J Hepatol. 2017 Nov;67(5):933-939
pubmed: 28627363
Hepatology. 2007 Mar;45(3):579-87
pubmed: 17326216
Hepatol Res. 2008 Jan;38(1):37-51
pubmed: 18039202
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Gastroenterology. 2019 May;156(6):1683-1692.e1
pubmed: 30660729
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Dig Dis Sci. 2017 Oct;62(10):2932-2942
pubmed: 28884320
Hepatology. 2000 Aug;32(2):228-32
pubmed: 10915728
Oncology. 2007;72 Suppl 1:132-8
pubmed: 18087194
J Hepatol. 2005 Feb;42(2):225-9
pubmed: 15664248
J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:88-92
pubmed: 24251711
Hepatol Res. 2012 Jun;42(6):564-73
pubmed: 22257119
Hepatology. 2018 Sep;68(3):827-838
pubmed: 29377196
Hepatology. 1999 Apr;29(4):1124-30
pubmed: 10094956
Hepatol Res. 2019 Feb;49(2):125-135
pubmed: 30307682
Gastroenterology. 2018 Aug;155(2):411-421.e4
pubmed: 29655836
J Gastroenterol. 2021 Jan;56(1):90-100
pubmed: 33278003
J Hepatol. 2019 Aug;71(2):265-273
pubmed: 30959157
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Hepatol Int. 2019 May;13(3):293-301
pubmed: 30820753
Liver Int. 2017 Aug;37(8):1122-1127
pubmed: 28423231
Gastroenterology. 2019 Nov;157(5):1264-1278.e4
pubmed: 31356807
J Hepatobiliary Pancreat Surg. 2001;8(5):435-40
pubmed: 11702253
Hepatology. 2006 Dec;44(6):1543-54
pubmed: 17133492
J Viral Hepat. 2020 Jul;27(7):690-698
pubmed: 32096310
J Gastroenterol. 2012 May;47(5):569-76
pubmed: 22187167
Front Med (Lausanne). 2021 Oct 18;8:744512
pubmed: 34733865
Gastroenterology. 2015 Sep;149(3):649-59
pubmed: 25985734
J Hepatol. 2016 Oct;65(4):719-726
pubmed: 27084592
Hepatol Res. 2015 Jan;45(2):152-61
pubmed: 25052449
Ann Intern Med. 2003 Feb 18;138(4):299-306
pubmed: 12585827
J Hepatol. 2019 Jan;70(1):78-86
pubmed: 30336183
PLoS One. 2020 May 22;15(5):e0233212
pubmed: 32442193
J Hepatol. 2010 Jun;52(6):889-94
pubmed: 20395009
Cancer Res. 1992 Mar 15;52(6):1504-9
pubmed: 1347253
Dig Dis Sci. 2019 Nov;64(11):3328-3336
pubmed: 31041639